Chapter 3. Neurophysiology: The Generation, Transmission, and Integration of Neural Signals
Follow us on Facebook and Twitter, or subscribe to our mailing list, to receive news updates. Learn more.
Jon Hamilton The simple act of thinking can accelerate the growth of many brain tumors. That's the conclusion of a paper in Cell published Thursday that showed how activity in the cerebral cortex affected high-grade gliomas, which represent about 80 percent of all malignant brain tumors in people. "This tumor is utilizing the core function of the brain, thinking, to promote its own growth," says Michelle Monje, a researcher and neurologist at Stanford who is the paper's senior author. In theory, doctors could slow the growth of these tumors by using sedatives or other drugs to reduce mental activity, Monje says. But that's not a viable option because it wouldn't eliminate the tumor and "we don't want to stop people with brain tumors from thinking or learning or being active." Even so, the discovery suggests other ways to slow down some of the most difficult brain tumors, says Tracy Batchelor, who directs the neuro-oncology program at Massachusetts General Hospital and was not involved in the research. "We really don't have any curative treatments for high-grade gliomas," Batchelor says. The discovery of a link between tumor growth and brain activity "has opened up a window into potential therapeutic interventions," he says. The discovery came from a team of scientists who studied human glioma tumors implanted in mouse brains. The scientists used a technique called optogenetics, which uses light to control brain cells, to increase the activity of cells near the tumors. © 2015 NPR
Link ID: 20846 - Posted: 04.25.2015
By Antonio Regalado Various powerful new tools for exploring and manipulating the brain have been developed over the last few years. Some use electronics, while others use light or chemicals. At one MIT lab, materials scientist Polina Anikeeva has hit on a way to manufacture what amounts to a brain-science Swiss Army knife. The neural probes she builds carry light while collecting and transmitting electricity, and they also have tiny channels through which to pump drugs. That’s an advance over metal wires or silicon electrodes conventionally used to study neurons. Anikeeva makes the probes by assembling polymers and metals into large-scale blocks, or preforms, and then stretching them into flexible, ultrathin fibers. Multifunctional fibers offer new ways to study animal behavior, since they can record from neurons as well as stimulating them. New types of medical technology could also result. Imagine, as Anikeeva does, bionic wiring that bridges a spinal-cord injury, collecting electrical signals from the brain and transmitting them to the muscles of a paralyzed hand. Anikeeva made her first multifunctional probe while studying at Stanford. It was crude: she simply wrapped metal wires around a glass filament. But this made it possible to combine standard electrode measurements with a new technology, optogenetics, in which light is fired at neurons to activate them or shut them down.
Keyword: Brain imaging
Link ID: 20832 - Posted: 04.22.2015
Heidi Ledford An experimental antibody drug aimed at protecting nerves from the ravages of multiple sclerosis offers hope for a new way to combat the neurological disease — if researchers can definitively show that it works. The antibody, anti-LINGO-1, is intended to stimulate regrowth of the myelin sheath, the fatty protective covering on nerve cells that is damaged by multiple sclerosis. Its developer, Biogen of Cambridge, Massachusetts, will present results from a small clinical trial at an American Academy of Neurology meeting this week in Washington DC. If the initial promising results from the trial are confirmed, it will be the first such myelin-regeneration therapy. Other researchers are racing to find more targets and compounds that act similarly. “Once we get a positive result, the field will move very quickly,” says Jack Antel, a neurologist at McGill University in Montreal, Canada. But that excitement is tempered by practical hurdles: there is as yet no proven way to measure remyelination of nerve cells in living humans. Myelin sheaths insulate and support axons, the fibres that transmit signals between nerve cells. In multiple sclerosis, immune attack destroys these sheaths. Stripped of this protective coating, the axons gradually wither away, causing the numbness and muscle spasms that are characteristic of the disease. The 12 drugs approved in the United States to treat multiple sclerosis slow this immune attack — although sometimes with dangerous side effects. But none stops it, says Bruce Trapp, a neuroscientist at the Cleveland Clinic in Ohio. © 2015 Nature Publishing Group
Two drugs already on the market — an antifungal and a steroid — may potentially take on new roles as treatments for multiple sclerosis. According to a study published in Nature today, researchers discovered that these drugs may activate stem cells in the brain to stimulate myelin producing cells and repair white matter, which is damaged in multiple sclerosis. The study was partially funded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health. Specialized cells called oligodendrocytes lay down multiple layers of a fatty white substance known as myelin around axons, the long “wires” that connect brain cells. Myelin acts as an insulator and enables fast communication between brain cells. In multiple sclerosis there is breakdown of myelin and this deterioration leads to muscle weakness, numbness and problems with vision, coordination and balance. “To replace damaged cells, the scientific field has focused on direct transplantation of stem cell-derived tissues for regenerative medicine, and that approach is likely to provide enormous benefit down the road. We asked if we could find a faster and less invasive approach by using drugs to activate native nervous system stem cells and direct them to form new myelin. Our ultimate goal was to enhance the body’s ability to repair itself,” said Paul J. Tesar, Ph.D., associate professor at Case Western Reserve School of Medicine in Cleveland, and senior author of the study. It is unknown how myelin-producing cells are damaged, but research suggests they may be targeted by malfunctioning immune cells and that multiple sclerosis may start as an autoimmune disorder. Current therapies for multiple sclerosis include anti-inflammatory drugs, which help prevent the episodic relapses common in multiple sclerosis, but are less effective at preventing long-term disability. Scientists believe that therapies that promote myelin repair might improve neurologic disability in people with multiple sclerosis.
Carl Zimmer In 1998, Dr. Philip A. Starr started putting electrodes in people’s brains. A neurosurgeon at the University of California, San Francisco, Dr. Starr was treating people with Parkinson’s disease, which slowly destroys essential bits of brain tissue, robbing people of control of their bodies. At first, drugs had given his patients some relief, but now they needed more help. After the surgery, Dr. Starr closed up his patients’ skulls and switched on the electrodes, releasing a steady buzz of electric pulses in their brains. For many patients, the effect was immediate. “We have people who, when they’re not taking their meds, can be frozen,” said Dr. Starr. “When we turn on the stimulator, they start walking.” First developed in the early 1990s, deep brain stimulation, or D.B.S., was approved by the Food and Drug Administration for treating Parkinson’s disease in 2002. Since its invention, about 100,000 people have received implants. While D.B.S. doesn’t halt Parkinson’s, it can turn back the clock a few years for many patients. Yet despite its clear effectiveness, scientists like Dr. Starr have struggled to understand what D.B.S. actually does to the brain. “We do D.B.S. because it works,” said Dr. Starr, “but we don’t really know how.” In a recent experiment, Dr. Starr and his colleagues believe they found a clue. D.B.S. may counter Parkinson’s disease by liberating the brain from a devastating electrical lock-step. The new research, published on Monday in Nature Neuroscience, may help scientists develop better treatments for Parkinson’s disease. It may also help researchers adapt D.B.S. for treatment of such brain disorders as depression and obsessive compulsive disorder. © 2015 The New York Times Company
Link ID: 20817 - Posted: 04.18.2015
By Lenny Bernstein Children with two of the most severe forms of epilepsy can suffer scores of seizures each day, as well as long-term physical and cognitive problems. The two conditions, Dravet and Lennox-Gastaut syndromes, are quite rare but unfortunately very resistant to treatment with current epilepsy drugs. Now a compound found in marijuana plants has shown promising results in a preliminary study, during which it sharply reduced the number of seizures suffered by these children. Some were even seizure-free after three months of taking the drug, cannabidiol, the research showed. "We're very encouraged by the data," said Orrin Devinsky, director of the NYU Langone Comprehensive Epilepsy Center and leader of the research. A more rigorous study of cannabidiol's impact has begun and will help determine how effective it really is, he said. In making cannabidiol, the marijuana plant's psychoactive material (THC) was removed. A 99 percent pure liquid version of the drug was given for three to six months to 137 people with the two syndromes. Most were children (the subjects ranged in age from 2 to 26), and before the experiment they suffered a disturbing average of 95.3 convulsive seizures every month. Convulsive seizures are the more severe, violent kind; people with epilepsy can experience a wide variety of seizures, including some mild enough that they appear to be merely staring into space for a few seconds. Some of the subjects had taken as many as 10 different epilepsy drugs, with little success.
By Jennifer Couzin-Frankel Sudden death, a mysterious and devastating outcome of epilepsy, could result from a brain stem shutdown following a seizure, researchers report today in Science Translational Medicine. Although the idea is still preliminary, it’s engendering hope that neurologists are one step closer to intervening before death strikes. Sudden unexpected death in epilepsy (SUDEP) has long bedeviled doctors and left heartbroken families in its wake. “It’s as big a mystery as epilepsy itself,” says Jeffrey Noebels, a neurologist at Baylor College of Medicine in Houston, Texas, and the senior author of the new paper. As its name suggests, SUDEP attacks without warning: People with epilepsy are found dead, often following a seizure, sometimes face down in bed. Many are young—the median age is 20—and patients with uncontrolled generalized seizures, the most severe type, are at highest risk. About 3000 people are thought to die of SUDEP each year in the United States. And doctors have struggled to understand why. “How can you have seizures your whole life, and all of a sudden, it’s your last one?” Noebels asks. In 2013, an international team of researchers described its study of epilepsy patients who had died while on hospital monitoring units. In 10 SUDEP cases for which they had the patients’ heart function and breathing patterns, the authors found that the patients’ cardiorespiratory systems collapsed over several minutes, and their brain activity was severely depressed. “Their EEG went flat after a seizure,” says Stephan Schuele, an epileptologist at Northwestern University Feinberg School of Medicine in Chicago, Illinois, who wasn’t involved in the study. © 2015 American Association for the Advancement of Science
Link ID: 20782 - Posted: 04.10.2015
|By Simon Makin People can control prosthetic limbs, computer programs and even remote-controlled helicopters with their mind, all by using brain-computer interfaces. What if we could harness this technology to control things happening inside our own body? A team of bioengineers in Switzerland has taken the first step toward this cyborglike setup by combining a brain-computer interface with a synthetic biological implant, allowing a genetic switch to be operated by brain activity. It is the world's first brain-gene interface. The group started with a typical brain-computer interface, an electrode cap that can register subjects' brain activity and transmit signals to another electronic device. In this case, the device is an electromagnetic field generator; different types of brain activity cause the field to vary in strength. The next step, however, is totally new—the experimenters used the electromagnetic field to trigger protein production within human cells in an implant in mice. The implant uses a cutting-edge technology known as optogenetics. The researchers inserted bacterial genes into human kidney cells, causing them to produce light-sensitive proteins. Then they bioengineered the cells so that stimulating them with light triggers a string of molecular reactions that ultimately produces a protein called secreted alkaline phosphatase (SEAP), which is easily detectable. They then placed the human cells plus an LED light into small plastic pouches and inserted them under the skin of several mice. © 2015 Scientific American
Hannah Devlin, science correspondent Scientists have raised the alert about an antibiotic routinely prescribed for chest infections, after linking it to an increased risk of epilepsy and cerebral palsy in children whose mothers took the drug during pregnancy. Children of mothers who had taken macrolide antibiotics were found to be almost twice as likely to be affected by the conditions, prompting scientists to call for a review of their use during pregnancy. The study authors urged pregnant women not to stop taking prescribed antibiotics, however. The potential adverse effects are rare and, as yet, unproven, while infections during pregnancy are a well-established cause of health problems in babies. Professor Ruth Gilbert, a clinical epidemiologist who led the research at University College London, said: “The main message is for medicines regulators and whether they need to issue a warning about these drugs. For women, if you’ve got a bacterial infection, it’s more important to get on and treat it.” The study tracked the children of nearly 65,000 women who had been prescribed a variety of antibiotics for illnesses during pregnancy, including chest and throat infections and cystitis. There was no evidence that most antibiotics (including penicillin, which made up 67% of prescriptions), led to an increased risk of the baby developing cerebral palsy or epilepsy. However, when the antibiotics were compared head-to-head, the potential adverse effect of macrolide drugs emerged. Around 10 in 1,000 children whose mothers were given the drug had developed the conditions by the age of seven, compared to 6 in 1,000 children, for those who had other types of antibiotic. © 2015 Guardian News and Media Limited
Mo Costandi Two teams of scientists have developed new ways of stimulating neurons with nanoparticles, allowing them to activate brain cells remotely using light or magnetic fields. The new methods are quicker and far less invasive than other hi-tech methods available, so could be more suitable for potential new treatments for human diseases. Researchers have various methods for manipulating brain cell activity, arguably the most powerful being optogenetics, which enables them to switch specific brain cells on or off with unprecedented precision, and simultaneously record their behaviour, using pulses of light. This is very useful for probing neural circuits and behaviour, but involves first creating genetically engineered mice with light-sensitive neurons, and then inserting the optical fibres that deliver light into the brain, so there are major technical and ethical barriers to its use in humans. Nanomedicine could get around this. Francisco Bezanilla of the University of Chicago and his colleagues knew that gold nanoparticles can absorb light and convert it into heat, and several years ago they discovered that infrared light can make neurons fire nervous impulses by heating up their cell membranes. They therefore attached gold nanorods to three different molecules that recognise and bind to proteins in the cell membranes – the scorpion toxin Ts1, which binds to a sodium channel involved in producing nervous impulses, and antibodies that bind the P2X3 and the TRPV1 channels, both found in dorsal root ganglion (DRG) neurons, which transmit touch and pain information up the spinal cord and into the brain. © 2015 Guardian News and Media Limited
Keyword: Brain imaging
Link ID: 20717 - Posted: 03.25.2015
By Emily Underwood Deep brain stimulation, which now involves surgically inserting electrodes several inches into a person's brain and connecting them to a power source outside the skull, can be an extremely effective treatment for disorders such as Parkinson's disease, obsessive compulsive disorder, and depression. The expensive, invasive procedure doesn't always work, however, and can be risky. Now, a study in mice points to a less invasive way to massage neuronal activity, by injecting metal nanoparticles into the brain and controlling them with magnetic fields. Major technical challenges must be overcome before the approach can be tested in humans, but the technique could eventually provide a wireless, nonsurgical alternative to traditional deep brain stimulation surgery, researchers say. "The approach is very innovative and clever," says Antonio Sastre, a program director in the Division of Applied Science & Technology at the National Institute of Biomedical Imaging and Bioengineering in Bethesda, Maryland. The new work provides "a proof of principle." The inspiration to use magnets to control brain activity in mice first struck materials scientist Polina Anikeeva while working in the lab of neuroscientist-engineer Karl Deisseroth at Stanford University in Palo Alto, California. At the time, Deisseroth and colleagues were refining optogenetics, a tool that can switch specific ensembles of neurons on and off in animals with beams of light. © 2015 American Association for the Advancement of Science.
Keyword: Brain imaging
Link ID: 20690 - Posted: 03.14.2015
By Lizzie Wade SAN JOSE, CALIFORNIA—Humans have been using cannabis for more than 5000 years. So why don’t scientists know more about it? Three experts gathered here at the annual meeting of AAAS (which publishes Science) to discuss what scientists and doctors know about the drug and what they still need to learn. “By the end of this session, you’ll know more about cannabis than your physician does,” said Mark Ware, a family physician at the McGill University Health Center in Montreal, Canada, who organized the talk. How does marijuana work? Our brains are primed to respond to marijuana, because “there are chemicals in our own bodies that act like THC [the psychoactive ingredient in pot]” and other compounds in cannabis called cannabinoids, explained Roger Pertwee, a neuropharmacologist at the University of Aberdeen in the United Kingdom who has studied cannabinoids since the 1960s. Cannabinoids produced by our bodies or ingested through marijuana use react with a series of receptors in our brains called the endocannabinoid system, which is involved in appetite, mood, memory, and pain sensation. Scientists have discovered 104 cannabinoids so far, but “the pharmacology of most of them has yet to be investigated,” Pertwee said. What are the known medical uses of marijuana? Marijuana has been used for decades to stimulate appetite and treat nausea and vomiting, especially in patients undergoing chemotherapy. Its success in easing the symptoms of multiple sclerosis patients led to the development of Sativex, a drug manufactured by GW Pharmaceuticals that includes THC and cannabidiol (CBD), a cannabinoid that isn’t psychoactive. © 2015 American Association for the Advancement of Science
By Ben Thomas The past several years have brought two parallel revolutions in neuroscience. Researchers have begun using genetically encoded sensors to monitor the behavior of individual neurons, and they’ve been using brief pulses of light to trigger certain types of neurons to activate. These two techniques are known collectively as optogenetics—the science of using light to read and activate genetically specified neurons—but until recently, most researchers have used them separately. Though many had tried, no one had succeeded in combining optogenetic readout and stimulation into one unified system that worked in the brains of living animals. But now, a team led by Michael Hausser, a neuroscientist at University College London’s Wolfson Institute for Biomedical Research, has succeeded in creating just such a unified optogenetic input/output system. In a paper published this January in the journal Nature Methods [Scientific American is part of the Nature Publishing Group], the team explain how they’ve used the system to record complex signaling codes used by specific sets of neurons and to “play” those codes back by reactivating the same neural firing patterns they recorded, paving the way to get neural networks in the brains of living animals to recognize and respond to the codes they send. “This is going to be a game-changer,” Hausser says. Conventional optogenetics starts with genes. Certain genes encode instructions for producing light-sensitive proteins. By introducing these genes into brain cells, researchers are able to trick specific populations of those cells—all the neurons in a given brain region that respond to dopamine, for example—to fire their signals in response to tiny pulses of light. © 2015 Scientific American
Keyword: Brain imaging
Link ID: 20514 - Posted: 01.23.2015
John Markoff MENLO PARK, CALIF. — Ann Lam delicately places a laboratory slide holding a slice of brain from a living human onto a small platform in a room the size of a walk-in refrigerator. She closes a heavy door and turns to a row of computers to monitor her experiments. She is using one of the world’s most sophisticated and powerful microscopes, the Stanford Synchrotron Radiation Lightsource, to learn about the distribution of metals in the brains of epilepsy patients. But she has another reason for being here as well. Traditional techniques for staining brain tissue produce byproducts and waste that are hazardous to the environment. And often, this sort of research is performed on animals, something Dr. Lam insists on avoiding. The radiation that illuminates the Stanford microscope was once a waste product produced by the particle accelerators. Now that it has been harnessed — recycled, in a sense — she is able to use it to examine tissue removed from living human patients, not animals. For Dr. Lam, those are important considerations. Indeed, scientists like her worry that neuroscience has become a dirty business. Too often, they say, labs are stocked with toxic chemicals, dangerous instruments and hapless animal subjects. Funding often comes from the military, and some neuroscientists fear their findings may soon be applied in ways that they never intended, raising moral questions that are seldom addressed. In 2012, Dr. Lam and Dr. Elan Ohayon, her husband, founded the Green Neuroscience Laboratory in a former industrial building in the Convoy District, an up-and-coming San Diego neighborhood. Solar panels rest on the roof, and a garden is lovingly tended on the second floor. © 2015 The New York Times Company
Three-year outcomes from an ongoing clinical trial suggest that high-dose immunosuppressive therapy followed by transplantation of a person's own blood-forming stem cells may induce sustained remission in some people with relapsing-remitting multiple sclerosis (RRMS). RRMS is the most common form of MS, a progressive autoimmune disease in which the immune system attacks the brain and spinal cord. The trial is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted by the NIAID-funded Immune Tolerance Network (ITN) External Web Site Policy. Three years after the treatment, called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant or HDIT/HCT, nearly 80 percent of trial participants had survived without experiencing an increase in disability, a relapse of MS symptoms or new brain lesions. Investigators observed few serious early complications or unexpected side effects, although many participants experienced expected side effects of high-dose immunosuppression, including infections and gastrointestinal problems. The three-year findings are published in the Dec. 29, 2014, online issue of JAMA Neurology. “These promising results support the need for future studies to further evaluate the benefits and risks of HDIT/HCT and directly compare this treatment strategy to current MS therapies,” said NIAID Director Anthony S. Fauci, M.D. “If the findings from this study are confirmed, HDIT/HCT may become a potential therapeutic option for people with this often-debilitating disease, particularly those who have not been helped by standard treatments.”
Mo Costandi A team of neuroscientists at University College London has developed a new way of simultaneously recording and manipulating the activity of multiple cells in the brains of live animals using pulses of light. The technique, described today in the journal Nature Methods, combines two existing state-of-the-art neurotechnologies. It may eventually allow researchers to do away with the cumbersome microelectrodes they traditionally used to probe neuronal activity, and to interrogate the brain’s workings at the cellular level in real time and with unprecedented detail. One of them is optogenetics. This involves creating genetically engineered mice expressing algal proteins called Channelrhodopsins in specified groups of neurons. This renders the cells sensitive to light, allowing researchers to switch the cells on or off, depending on which Channelrhodopsin protein they express, and which wavelength of light is used. This can be done on a millisecond-by-millisecond timescale, using pulses of laser light delivered into the animals’ brains via an optical fibre. The other is calcium imaging. Calcium signals are crucial for just about every aspect of neuronal function, and nerve cells exhibit a sudden increase in calcium ion concentration when they begin to fire off nervous impulses. Using dyes that give off green fluorescence in response to increases in calcium concentration, combined with two-photon microscopy, researchers can detect this signature to see which cells are activated. In this way, they can effectively ‘read’ the activity of entire cell populations in brain tissue slices or live brains. Calcium-sensitive dyes are injectable, so targeting them with precision is difficult, and more recently, researchers have developed genetically-encoded calcium sensors to overcome this limitation. Mice can be genetically engineered to express these calcium-sensitive proteins in specific groups of cells; like the dyes before them, they, too, fluoresce in response to increases in calcium ion concentrations in the cells expressing them.
Keyword: Brain imaging
Link ID: 20441 - Posted: 12.23.2014
By Lenny Bernstein There are 60 million epileptics on the planet, and while advances in medication and implantable devices have helped them, the ability to better detect and even predict when they will have debilitating seizures would be a significant improvement in their everyday lives. Imagine, for example, if an epileptic knew with reasonable certainty that his next seizure would not occur for an hour or a day or a week. That might allow him to run to the market or go out for the evening or plan a short vacation with less concern. Computers and even dogs have been tested in the effort to do this, but now a group of organizations battling epilepsy is employing "big data" to help. They sponsored an online competition that drew 504 entrants who tried to develop algorithms that would detect and predict epileptic seizures. Instead of the traditional approach of asking researchers in a handful of labs to tackle the problem, the groups put huge amounts of data online that was recorded from the brains of dogs and people as they had seizures over a number of months. They then challenged anyone interested to use the information to develop detection and prediction models. "Seizure detection and seizure prediction," said Walter J. Koroshetz, deputy director of the National Institute of Neurological Disorders and Stroke (NINDS), are "two fundamental problems in the field that are poised to take significant advantage of large data computation algorithms and benefit from the concept of sharing data and generating reproducible results."
Link ID: 20403 - Posted: 12.08.2014
by Hal Hodson Yet another smartwatch launched this week. Called Embrace, it is rather different from the latest offerings from Apple, Samsung and Motorola: it can spot the warning signs of an epileptic seizure. Embrace was developed by Matteo Lai and his team at a firm called Empatica, with the help of Rosalind Picard at the Massachusetts Institute of Technology. It measures the skin's electrical activity as a proxy for changes deep in the brain, and uses a model built on years of clinical data to tell which changes portend a seizure. It also gathers the usual temperature and motion data that smartwatches collect, allowing the wearer to measure physical activity and sleep quality. Empatica launched a crowdfunding campaign on Indiegogo on Tuesday and has already raised more than $120,000. Backers who pledge $169 will receive an Embrace watch. The idea for the wristband came when Picard and her colleagues were running a study on the emotional states of children with autism, measuring skin conductance at the wrist as part of the study. Picard noticed that one of the children had registered a spike in electrical activity that turned out to have happened 20 minutes before they noticed the symptoms of a seizure. "It shocked me when I realised these things were showing up on the wrist," says Picard. The whole point of Embrace is to prevent sudden unexplained death in epilepsy (SUDEP). Its causes are not fully understood, but Picard says they understand enough to know how to reduce the chances of dying after an epileptic seizure. © Copyright Reed Business Information Ltd.
By Esther Hsieh A little-known fact: the tongue is directly connected to the brain stem. This anatomical feature is now being harnessed by scientists to improve rehabilitation. A team at the University of Wisconsin–Madison recently found that electrically stimulating the tongue can help patients with multiple sclerosis (MS) improve their gait. MS is an incurable disease in which the insulation around the nerves becomes damaged, disrupting the communication between body and brain. One symptom is loss of muscle control. In a study published in the Journal of Neuro-Engineering and Rehabilitation, Wisconsin neuroscientist Yuri Danilov and his team applied painless electrical impulses to the tip of the tongue of MS patients during physical therapy. Over a 14-week trial, patients who got tongue stimulation improved twice as much on variables such as balance and fluidity as did a control group who did the same regimen without stimulation. The tongue has extensive motor and sensory integration with the brain, Danilov explains. The nerves on the tip of the tongue are directly connected to the brain stem, a crucial hub that directs basic bodily processes. Previous research showed that sending electrical pulses through the tongue activated the neural network for balance; such activation may shore up the circuitry weakened by MS. The team is also using tongue stimulation to treat patients with vision loss, stroke damage and Parkinson's. “We have probably discovered a new way for the neurorehabilitation of many neurological disorders,” Danilov says. © 2014 Scientific American
Keyword: Multiple Sclerosis
Link ID: 20332 - Posted: 11.20.2014
By DENISE GRADY An electrical device glued to the scalp can slow cancer growth and prolong survival in people with the deadliest type of brain tumor, researchers reported on Saturday. The device is not a cure and, on average, adds only a few months of life when used along with the standard regimen of surgery, radiation and chemotherapy. Some doctors have questioned its usefulness. But scientists conducting a new study said the device was the first therapy in a decade to extend life in people with glioblastomas, brain tumors in which median survival is 15 months even with the best treatment. The disease affects about 10,000 people a year in the United States and is what killed Senator Edward M. Kennedy in 2009. It is so aggressive and hard to treat that even seemingly small gains in survival are considered important. The new findings mean the device should become part of the standard care offered to all patients with newly diagnosed glioblastomas, the researchers conducting the study said. The equipment consists of four pads carrying transducer arrays that patients glue to their scalps and change every few days. Wires lead to a six-pound operating system and power supply. Except for some scalp irritation, the device has no side effects, the study found. But patients have to wear it more or less around the clock and must keep their heads shaved. It generates alternating, low-intensity electrical fields — so-called tumor-treating fields — that can halt tumor growth by stopping cells from dividing, which leads to their death. The researchers said the technology might also help treat other cancers, and would be tested in mesothelioma and cancers of the lung, ovary, breast and pancreas. © 2014 The New York Times Company
Link ID: 20319 - Posted: 11.17.2014